Androgen-deprivation therapy plus abiraterone and prednisolone vs combined androgen blockade for high-risk, metastatic, castration-sensitive prostate cancer : A randomized controlled trial
Not Applicable
- Conditions
- high-risk, metastatic, castration-sensitive prostate cancer
- Registration Number
- JPRN-UMIN000035933
- Lead Sponsor
- Osaka General Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Cases with no prostate biopsy 2. Cases with other cancers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method time to biochemical recurrence (prostate specific antigen failure)
- Secondary Outcome Measures
Name Time Method